Small molecule screening guided by AI derived computational analyses in colon and ovarian tumors
Closed Special Notice Posted
This opportunity was awarded. See the award notice from , or the latest solicitation from .
- Solicitation number
- 75N95025Q00058
- Agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institute on Drug Abuse (NIDA) of the National Institutes of Health has published a Special Notice for a non-competitive contract award to EditCo Bio for small molecule screening guided by AI-derived computational analyses in colon and ovarian tumors. The purpose of the procurement is to acquire two SFRP1-HiBiT-tagged cell lines made by EditCo for the Functional Genomics Lab to quantify the expression of the SFRP1 gene when the cell lines are treated with small molecules.
The Special Notice states that the procurement will be conducted under the simplified acquisition procedures of FAR Part 13, which exempts it from the full and open competition requirements of FAR Part 6. EditCo Bio is identified as the sole source for the required services. The period of performance is estimated to be 20 weeks. Interested parties may submit capability statements, proposals, or quotations, which the agency will consider in determining whether to proceed on a non-competitive basis or conduct a competitive procurement. Response instructions include providing unit price, delivery period, prompt payment discount terms, and other details, and must be submitted electronically by the closing date of December 2, 2024.
Notice text
INTRODUCTION
THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).
The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA) the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to EditCo Bio 600 Saginaw DriveRedwood City, CA 94063 for small molecule screening guided by AI derived computational analyses in colon and ovarian tumors.
NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE and SET ASIDE STATUS
The intended procurement is classified under NAICS code 541380 Testing Laboratories and Services with a Size Standard of $16.50.
REGULATORY AUTHORITY
This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures. Contracts awarded using FAR Part 13—Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6—Competition Requirements. FAR Subpart 13.106-1 (b) Soliciting from a single source provides that: For purchases not exceeding the simplified acquisition threshold, Contracting officers may solicit from one source IF the contracting officer determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name OR industrial mobilization).
The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2022-08 dated October 22, 2022.
DESCRIPTION OF REQUIREMENT
PURPOSE AND OBJECTIVES:
The purpose of this procurement is the acquisition of two SFRP1-HiBiT-tagged cells lines made by EditCo for the Functional Genomics Lab. We require EditCo to use their custom cell engineering services to help us create two SFRP1-HiBiT-tagged cell lines to quantify the amount of the gene of interest, SFRP1, that is expressed when the cell lines are treated with small molecules.
Specific Requirements:
Edit, with the cell lines provided by the customer, will provide 2 SFRP1-HiBiT tagged cell lines.
SFRP1-HiBiT-tagged cell lines for small molecule screening:
• HCT116-SFRP1-HiBiT heterozygous knock-in
• HCT116-SFRP1-HiBiT homozygous knock-in
ESTIMATED PERIOD OF PERFORMANCE:
20 weeks ARO
CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATION
The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted. Specifically, EditCo Bio 600 Saginaw DriveRedwood City, CA 94063 is the only vendor in the marketplace that can provide the services required by NIDA .
The intended source is:
EditCo Bio 600 Saginaw DriveRedwood City, CA 94063
CLOSING STATEMENT
THIS SYNOPSIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. However, interested parties may identify their interest and capability to respond to this notice.
A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. All responsible sources may submit a capability statement, proposal, or quotation which shall be considered by the agency. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.
Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.
All responses must be received by the closing date and time of this announcement and must reference the solicitation number, 75N95025Q00058. Responses must be submitted electronically to Kaitlyn Landi, Contract Specialist, at kaitlyn.landi@nih.gov and KJ Shaikh, Contracting Officer, at kj.shaikh@nih.gov. U.S. Mail and fax responses will not be accepted.
Notice history
| Notice | Type | Posted |
|---|---|---|
| Assay Development Consultant Support Services | Award Notice | |
| Assay Development Consultant Support Services | Solicitation | |
| This notice | Special Notice |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Synthesis and Distribution of Drugs of Abuse and Related Compounds | National Institute on Drug Abuse | No set-aside | |
| Synthesis and Distribution of Drugs of Abuse and Related Compounds | National Institute on Drug Abuse | Total Small Business | |
| RNA sequencing and whole genome sequencing services | Office of Logisitics and Acquisition Operations | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity